China Pharma Holdings (CPHI) Cash & Equivalents (2010 - 2026)
China Pharma Holdings (CPHI) posted Cash & Equivalents of $168474.0 for Q1 2026, down 51.18% on a QoQ basis from $345112.0 in Q4 2025, and down 59.18% year-over-year from $412688.0 in Q1 2025.
China Pharma Holdings (CPHI) Cash & Equivalents (2010 - 2026) Analysis & Trends
China Pharma Holdings' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $168474.0 for Q1 2026.
- Quarterly Cash & Equivalents fell 59.18% year-over-year to $168474.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $168474.0 (down 59.18% YoY) and the FY2025 annual result came in at $345112.0, down 44.95% from the prior year.
- Cash & Equivalents was $168474.0 for Q1 2026 at China Pharma Holdings, down from $345112.0 in the prior quarter.
- Across five years, Cash & Equivalents topped out at $3.7 million in Q1 2022 and bottomed at $168474.0 in Q1 2026.
- A 5-year average of $1.2 million and a median of $838881.0 in 2024 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 594.97% — and 2023, when it sank 68.59%.
- China Pharma Holdings' Cash & Equivalents stood at $2.0 million in 2022, then decreased by 29.86% to $1.4 million in 2023, then plunged by 55.97% to $626879.0 in 2024, then plunged by 44.95% to $345112.0 in 2025, then slumped by 51.18% to $168474.0 in 2026.
- Business Quant data shows CPHI's Cash & Equivalents at $168474.0 in Q1 2026, $345112.0 in Q4 2025, and $267625.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | 168,474.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 168,474.00 |
| Dec 31, 2025 | 345,112.00 |
| Sep 30, 2025 | 267,625.00 |
| Jun 30, 2025 | 625,032.00 |
| Mar 31, 2025 | 412,688.00 |
| Dec 31, 2024 | 626,879.00 |
| Sep 30, 2024 | 718,691.00 |
| Jun 30, 2024 | 739,337.00 |
| Mar 31, 2024 | 838,881.00 |
| Dec 31, 2023 | 1.42 Mn |
| Sep 30, 2023 | 1.37 Mn |
| Jun 30, 2023 | 901,910.00 |
| Mar 31, 2023 | 1.17 Mn |
| Dec 31, 2022 | 2.03 Mn |
| Sep 30, 2022 | 2.10 Mn |
| Jun 30, 2022 | 2.20 Mn |
| Mar 31, 2022 | 3.71 Mn |
| Dec 31, 2021 | 4.86 Mn |
| Sep 30, 2021 | 500,000.00 |
| Jun 30, 2021 | 1.80 Mn |